BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 35961368)

  • 1. 68 Ga-FAPI PET/CT Detected Non-PSMA/FDG-Avid Primary Tumor in De Novo Metastatic Prostate Cancer.
    Pang Y; Meng T; Xu W; Shang Q; Chen H
    Clin Nucl Med; 2022 Dec; 47(12):1108-1111. PubMed ID: 35961368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visualization of Intermetastatic Heterogeneity in Mixed Neuroendocrine Carcinoma-Acinar Adenocarcinoma of the Prostate by 68 Ga-PSMA, 68 Ga-FAPI, and 18 F-FDG PET/CT.
    Cai J; Xu W; Meng T; Pang Y; Chen H
    Clin Nucl Med; 2023 Aug; 48(8):743-745. PubMed ID: 37220226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How accurate is
    Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast Activation Protein-Targeted PET/CT Imaging in a Treatment-Naive Prostate Cancer Patient With Low PSMA Expression.
    Mu X; Li M; Huang J; Wang Z; Fu W
    Clin Nucl Med; 2023 Nov; 48(11):e532-e534. PubMed ID: 37703425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of 68 Ga-DOTA-FAPI-04 PET/CT to Prostate Cancer Imaging : Complementary Role in PSMA-Negative Cases.
    Ergül N; Çermik TF; Alçın G; Arslan E; Erol Fenercioğlu Ö; Beyhan E; Şahin R; Baloğlu MC; Baykal Koca S; Türkay R; Yücetaş U
    Clin Nucl Med; 2024 Mar; 49(3):e105-e110. PubMed ID: 38271254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 68Ga-PSMA and 68Ga-FAPI-04 PET/CT Findings With 18F-FDG PET/CT in a Patient With Recurrent Prostate Cancer.
    Tatar G; Ergül N; Baloğlu MC; Arslan E; Çermik TF
    Clin Nucl Med; 2023 Mar; 48(3):e135-e137. PubMed ID: 36723899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of the diagnostic utility of
    Vlachostergios PJ; Niaz MJ; Thomas C; Christos PJ; Osborne JR; Margolis DJA; Khani F; Bander NH; Scherr DS; Tagawa ST
    Prostate; 2022 Mar; 82(4):483-492. PubMed ID: 34985786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of [
    Zhao L; Pang Y; Zheng H; Han C; Gu J; Sun L; Wu H; Wu S; Lin Q; Chen H
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3606-3617. PubMed ID: 33792760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Evaluation of
    Lopci E; Lughezzani G; Castello A; Saita A; Colombo P; Hurle R; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Casale P; Pietro D; Bevilacqua G; Balzarini L; Buffi NM; Guazzoni G; Lazzeri M
    Eur Urol Focus; 2021 Jul; 7(4):764-771. PubMed ID: 32312701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory analysis of 64 CuCl 2 PET-CT imaging in carcinoma prostate and its comparison with 68 Ga-PSMA-11 and 18 F-FDG PET-CT.
    Nazar AK; Kalshetty A; Chakravarty R; Chakraborty S; Basu S
    Nucl Med Commun; 2023 Oct; 44(10):910-923. PubMed ID: 37578310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of
    Chen R; Wang Y; Shi Y; Zhu Y; Xu L; Huang G; Liu J
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2970-2977. PubMed ID: 33528607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
    Yilmaz B; Turkay R; Colakoglu Y; Baytekin HF; Ergul N; Sahin S; Tugcu V; Inci E; Tasci AI; Cermik TF
    Prostate; 2019 Jun; 79(9):1007-1017. PubMed ID: 31012125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Comparison of
    Lan L; Zhang S; Xu T; Liu H; Wang W; Feng Y; Wang L; Chen Y; Qiu L
    Radiology; 2022 Sep; 304(3):648-657. PubMed ID: 35579524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved cancer detection in Waldeyer's tonsillar ring by
    Serfling S; Zhi Y; Schirbel A; Lindner T; Meyer T; Gerhard-Hartmann E; Lapa C; Hagen R; Hackenberg S; Buck AK; Scherzad A
    Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1178-1187. PubMed ID: 33057927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental Impact of [
    Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accurate preoperative staging with [
    Chen S; Chen Z; Zou G; Zheng S; Zheng K; Zhang J; Huang C; Yao S; Miao W
    Eur Radiol; 2022 Sep; 32(9):6070-6079. PubMed ID: 35352157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 68 Ga-PSMA-Avid Liver Metastases From Colon Cancer, Not Visualized on FDG PET Scan.
    Doroudinia A; Chekuri S
    Clin Nucl Med; 2023 Nov; 48(11):e547-e548. PubMed ID: 37756469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings.
    Arslan E; Ergül N; Beyhan E; Erol Fenercioglu Ö; Sahin R; Cin M; Battal Havare S; Can Trabulus FD; Mermut Ö; Akbas S; Fikret Çermik T
    Nucl Med Commun; 2023 Apr; 44(4):284-290. PubMed ID: 36756767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of
    Pang Y; Zhao L; Luo Z; Hao B; Wu H; Lin Q; Sun L; Chen H
    Radiology; 2021 Feb; 298(2):393-402. PubMed ID: 33258746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.